Physician profile
Robert F Wolf
NPI 1992781579
$3,966.26
in general payments reported to CMS, 2019-2025
26 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,179 · 2020: $445 · 2021: $83.35 · 2022: $147 · 2023: $208 · 2024: $499 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,524.19 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $432.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $358.35 | 2020 | |
| Abbvie INC. | $200.68 | 2019-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $194.52 | 2019-2020 | |
| Lilly USA, LLC | $180.03 | 2019-2025 | Mounjaro, Zepbound |
| Asahi Intecc USA, INC. | $134.75 | 2025 | Asahi Peripheral Vascular Wires |
| Astrazeneca Pharmaceuticals LP | $127.83 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Angiodynamics, INC. | $122.21 | 2024 | Auryon Laser System 100-120 Vac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.14 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $81.08 | 2019-2020 | |
| Abbott Laboratories | $77.68 | 2023-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $74.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $43.26 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $41.56 | 2024 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.55 | 2019 | |
| Dexcom, INC. | $38.88 | 2019-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $36.63 | 2019 | |
| Amarin Pharma, INC. | $33.51 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.16 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $28.83 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.82 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.29 | 2019 | |
| Shield Therapeutics INC | $12.43 | 2022 | |
| Horizon Therapeutics Plc | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.